Last reviewed · How we verify
Endostatins
Endostatins is a Small molecule drug developed by Guangzhou Double Bioproducts Co., Ltd. It is currently in Phase 3 development. Also known as: E10A, Endostar.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Endostatins |
|---|---|
| Also known as | E10A, Endostar |
| Sponsor | Guangzhou Double Bioproducts Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. (PHASE2)
- Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma (PHASE1, PHASE2)
- Evaluation of Calcinosis in Systemic Sclerosis
- Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer (PHASE1)
- Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (PHASE2)
- Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (PHASE2)
- Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level
- Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endostatins CI brief — competitive landscape report
- Endostatins updates RSS · CI watch RSS
- Guangzhou Double Bioproducts Co., Ltd portfolio CI
Frequently asked questions about Endostatins
What is Endostatins?
Who makes Endostatins?
Is Endostatins also known as anything else?
What development phase is Endostatins in?
Related
- Manufacturer: Guangzhou Double Bioproducts Co., Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: E10A, Endostar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing